Atara Biotherapeutics’ layoffs could leave the biotech with around 80 employees. The cuts follow news that the FDA rejected ...
H.C. Wainwright maintained its Neutral stance on Atara Biotherapeutics stock (NASDAQ:ATRA), following the company's announcement of a significant workforce reduction. According to InvestingPro data, ...
NEW YORK CITY, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Atara Biotherapeutics experiences a plunge in share prices after the Food and Drug Administration holds up approval of a drug ...
Atara Biotherapeutics will be completing its third large-scale layoff in four years after the biotech company announced that it would be shedding 50% of its workforce by the end of June. Atara, a ...
Atara Biotherapeutics (ATRA) plans to cut around 50% of its workforce, just a little over a week after the FDA declined to ...
T-cell immunotherapy company Atara Biotherapeutics closed 8% lower on Tuesday, having lost 41% of its stock market value on ...
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...
The biotech said it has dosed the first participant in a Phase 3 study of its in vivo gene editing treatment. Elsewhere, the FDA imposed a hold on Atara and lifted another on Amylyx.
Stifel analysts adjusted their outlook on Atara Biotherapeutics (NASDAQ:ATRA) stock, reducing the price target to $5 from the previous $10, while maintaining a Hold rating on the shares. The decision ...
On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback